Your browser doesn't support javascript.
loading
Minimally invasive thoracoscopic left atrial appendage occlusion compared with transcatheter left atrial appendage closure for stroke prevention in recurrent nonvalvular atrial fibrillation patients after radiofrequency ablation: a prospective cohort study.
Wang, Jian-Long; Zhou, Kuo; Qin, Zheng; Cheng, Wan-Jun; Zhang, Ling-Zhi; Zhou, Yu-Jie.
Afiliação
  • Wang JL; Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
  • Zhou K; Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
  • Qin Z; Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
  • Cheng WJ; Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
  • Zhang LZ; Interventional Department, Luanzhou People's Hospital, Tangshan, China.
  • Zhou YJ; Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerot1ic Disease, Clinical Center for Coronary Heart Disease, Beijing, China.
J Geriatr Cardiol ; 18(11): 877-885, 2021 Nov 28.
Article em En | MEDLINE | ID: mdl-34908925
BACKGROUND: Tanscatheter left atrial appendage (LAA) closure and minimally invasive thoracoscopic LAA occlusion are local interventions of LAA for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). However, the safety and efficacy of these methods have not been compared. This prospective cohort study aimed to assess the safety and efficacy of those two treatment approaches for stroke prevention in NVAF patients. METHODS: Two hundred and nine recurrent NVAF patients who received radiofrequency ablation were enrolled. These patients were treated with transcatheter LAA closure or thoracoscopic LAA occlusion. The patients were followed up from the first postoperative day and evaluated for efficacy endpoints (stroke/transient ischemic attack (TIA), systemic embolism (SE), and death) and a safety endpoint (bleeding events). Perioperative complications were recorded. RESULTS: After a median follow-up of 1.8 years (383 patient-years), the overall rate of the composite efficacy endpoints was similar between the two groups (3.8 vs. 2.7 events per 100 patient-years; HR = 0.71; 95% CI: 0.225-2.237; P = 0.559). However, regarding primary safety endpoint, there were 1.5 bleeding events per 100 patient-years in the thoracoscopic LAA occlusion group, compared with 6.4 in transcatheter LAA closure group (HR = 0.246; 95% CI: 0.074-0.819; P = 0.022). The incidence of operative complications was 3/138 (2.17%) in thoracoscopic LAA occlusion group and 1/71 (1.41%) in transcatheter LAA closure group. CONCLUSIONS: Thoracoscopic LAA occlusion and transcatheter LAA closure have similar efficacy in preventing stroke in NVAF patients. However, the thoracoscopic group had fewer bleeding events than the transcatheter group, but the former group required a longer hospital stay.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article